News | Proton Therapy | August 06, 2019

IBA Signs Contract to Install Proton Therapy Center in Kansas

Construction to host IBA’s Proteus One system expected to start later this year

IBA Signs Contract to Install Proton Therapy Center in Kansas

August 6, 2019 — IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution with The University of Kansas Health System. The contract includes a plan for a possible extension with a second ProteusOne unit in the future. The proton therapy center will be built at the Main Campus of The University of Kansas Health System in Kansas City, Kansas. Construction is anticipated to begin later this year.

The contract includes a long-term operation and maintenance agreement and the typical end-user price for a Proteus One solution, with a maintenance contract between EUR 35 and 40 million. IBA will begin to recognize revenue for the contract in the 2019 financial year.

Bob Page, president and chief executive officer  of The University of Kansas Health System commented, “We are excited to partner with IBA, the world’s leading proton therapy system provider, to bring proton therapy to Kansas City and the region. IBA’s Proteus One represents one of the most advanced solutions to delivering proton therapy. With the first system in place, and the ability to add a second system in the future, patients will be able to stay closer to home to receive the most advanced cancer care available.”

Proteus One is the compact intensity modulated proton therapy (IMPT) solution from IBA, benefiting from the latest technologies. The system is smaller, more affordable, easier to install and to operate.

For more information: www.iba-worldwide.com

Related Content

Major Radiology Organizations Publish Ethics of AI in Radiology Statement
News | Artificial Intelligence | October 22, 2019
Experts in the use of artificial intelligence (AI) in radiology, from many of the world’s leading radiology, medical...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 proton therapy system
News | Proton Therapy | October 07, 2019
ProTom International received 510(k) clearance from the U.S.
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 03, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a